Aromatase inhibitor-induced musculoskeletal symptoms (AIMSS) may present with arthralgia, myalgia, arthritis or stiffness, and it may be the reason for discontinuation of the treatment in approximately 25% of the patients with early breast cancer [14]. The gene discussed is CYP19A1; the disease is arthritic joint disease.